Negative Feedback of T Cell Activation Through Inhibitory Adapters and Costimulatory Receptors
Overview
General Surgery
Authors
Affiliations
Antigen recognition by the T cell receptor (TCR) complex induces the formation of a TCR signalosome by recruiting various signaling molecules, generating the recognition signals for T cell activation. The activation status and functional outcome are positively and negatively regulated by dynamic organization of the signalosome and by costimulation signals. We have studied the negative regulation of T cell activation, particularly through inhibitory adapters and costimulation receptors that are little expressed in resting cells but are induced upon T cell activation. We described Grb-associated binder 2 (Gab2) and cytotoxic T lymphocyte antigen-4 (CTLA-4) as a representative inhibitory adapter and a negative costimulation receptor, respectively, both of which exhibit negative feedback. Gab2 functions as a signal branch for activation vs. inhibition, as phosphorylation of either Src homology 2 (SH2) domain-containing leukocyte phosphoprotein of 76 kDa (SLP-76) or Gab2 by zeta-associated protein of 70 kDa (ZAP-70) determines the fate of the response. As a professional inhibitory receptor, CTLA-4 inhibits T cell response by competition of ligand binding with positive costimulator receptor CD28, and also induces inhibitory signaling. The trafficking and the cell surface expression of CTLA-4 are dynamically regulated and induced. CTLA-4 is accumulated in lysosomes and secreted to the T cell-APC contact site upon TCR stimulation. As T cell activation proceeds, these inhibitory adapters and costimulation receptors are induced and suppress/regulate the responses as negative feedback.
Mathematical models of TCR initial triggering.
Shi J, Yin W, Chen W Front Immunol. 2024; 15:1411614.
PMID: 39091495 PMC: 11291225. DOI: 10.3389/fimmu.2024.1411614.
Capelle C, Cire S, Hedin F, Hansen M, Pavelka L, Grzyb K Nat Commun. 2023; 14(1):7461.
PMID: 37985656 PMC: 10662447. DOI: 10.1038/s41467-023-43053-0.
Immune Checkpoint Inhibitors in Cancer Therapy-How to Overcome Drug Resistance?.
Lao Y, Shen D, Zhang W, He R, Jiang M Cancers (Basel). 2022; 14(15).
PMID: 35892835 PMC: 9331941. DOI: 10.3390/cancers14153575.
Pinto B, Medeiros N, Teixeira-Carvalho A, Fiuza J, Eloi-Santos S, Nunes M Front Cardiovasc Med. 2022; 9:750876.
PMID: 35665256 PMC: 9162138. DOI: 10.3389/fcvm.2022.750876.
Peripheral T cell lymphomas: from the bench to the clinic.
Fiore D, Cappelli L, Broccoli A, Zinzani P, Chan W, Inghirami G Nat Rev Cancer. 2020; 20(6):323-342.
PMID: 32249838 DOI: 10.1038/s41568-020-0247-0.